Eur Respir J 2003; 22:931-936
Copyright ©ERS Journals Ltd 2003
Longitudinal changes in the nature, severity and frequency of COPD exacerbations
G.C. Donaldson,
T.A.R. Seemungal,
I.S. Patel,
S.J. Lloyd-Owen,
T.M.A. Wilkinson and
J.A. Wedzicha
Academic Unit of Respiratory Medicine, St.Bartholomew's and Royal London School of Medicine and Dentistry, London, UK.
CORRESPONDENCE: J.A. Wedzicha, Academic Unit of Respiratory Medicine, Dominion House, St. Bartholomew's Hospital, London, EC1A 7BE, UK. Fax: 44 2076018616. E-mail: j.a.wedzicha@gmul.ac.uk
Keywords: chronic obstructive pulmonary disease, cohort studies, exacerbations
Received: April 7, 2003
Accepted September 3, 2003
This study was supported by the British Lung Foundation and GlaxoSmithKline.
Exacerbations are an important feature and outcome measure in chronic obstructive pulmonary disease (COPD), but little is known about changes in their severity, recovery, symptom composition or frequency over time.
In this study 132 patients (91 male; median age 68.4 yrs and median forced expiratory volume in one second (FEV1) 38.4% predicted) recorded daily symptoms and morning peak expiratory flow.
Patients were monitored for a median of 918 days and 1,111 exacerbations were identified. Patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) category III, n=38) had an annual exacerbation frequency of 3.43·yr1, 0.75·yr1 higher than those with moderate COPD (GOLD II, n=94). Exacerbation frequency did not change significantly during the study. At exacerbation onset, symptom count increased to 2.23, relative to a baseline of 0.36 set 814 days previously, and this increase rose by 0.05·yr1. Recovery to baseline levels in symptoms and FEV1 took longer (0.32 and 0.55 days·yr1). Sputum purulence at exacerbation became more prevalent over time by 4.1%·yr1 from an initial value of 17%.
The results of this study suggest that over time, individual patients have more symptoms during exacerbations, with an increased chance of sputum purulence and longer recovery times.
This article has been cited by other articles:

|
 |

|
 |
 
D. Makris, N. Tzanakis, A. Damianaki, E. Ntaoukakis, E. Neofytou, M. Zervou, N. M. Siafakas, and E. G. Tzortzaki
Microsatellite DNA instability and COPD exacerbations
Eur. Respir. J.,
September 1, 2008;
32(3):
612 - 618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Makris, S. Lazarou, M. Alexandrakis, T. V. Kourelis, N. Tzanakis, D. Kyriakou, and K. I. Gourgoulianis
Tc2 Response at the Onset of COPD Exacerbations
Chest,
September 1, 2008;
134(3):
483 - 488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J.,
February 1, 2008;
31(2):
416 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Abusriwil and R. A. Stockley
The Interaction of Host and Pathogen Factors in Chronic Obstructive Pulmonary Disease Exacerbations and Their Role in Tissue Damage
Proceedings of the ATS,
December 1, 2007;
4(8):
611 - 617.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sykes, P. Mallia, and S. L. Johnston
Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
December 1, 2007;
4(8):
642 - 646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
December 1, 2007;
4(8):
647 - 658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Young, R. Hopkins, and T. E. Eaton
Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes
Eur. Respir. J.,
October 1, 2007;
30(4):
616 - 622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Gunen, S. S. Hacievliyagil, O. Yetkin, G. Gulbas, L. C. Mutlu, and E. In
The role of nebulised budesonide in the treatment of exacerbations of COPD
Eur. Respir. J.,
April 1, 2007;
29(4):
660 - 667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. Wang, J.-M. Lin, C.-Y. Li, L.-T. Lee, Y.-L. Guo, and F.-C. Sung
Prevalence and Risks of Chronic Airway Obstruction: A Population Cohort Study in Taiwan
Chest,
March 1, 2007;
131(3):
705 - 710.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. G. Wood, H. Powell, T. Grissell, T. T.D. Nguyen, D. Shafren, M. Hensley, and P. G. Gibson
Persistent Airway Obstruction After Virus Infection Is Not Associated With Airway Inflammation
Chest,
February 1, 2007;
131(2):
415 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Mannino, M. M. Reichert, and K. J. Davis
Am. J. Respir. Crit. Care Med.,
February 1, 2007;
175(3):
292 - 292.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Takabatake, Y. Shibata, S. Abe, T. Wada, J.-i. Machiya, A. Igarashi, Y. Tokairin, G. Ji, H. Sato, M. Sata, et al.
A Single Nucleotide Polymorphism in the CCL1 Gene Predicts Acute Exacerbations in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
October 15, 2006;
174(8):
875 - 885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Mallia and S. L. Johnston
How viral infections cause exacerbation of airway diseases.
Chest,
October 1, 2006;
130(4):
1203 - 1210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D M Mannino and K J Davis
Lung function decline and outcomes in an elderly population
Thorax,
June 1, 2006;
61(6):
472 - 477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Wedzicha and T. Wilkinson
Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers
Proceedings of the ATS,
May 1, 2006;
3(3):
218 - 221.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Scott, P Walker, and P M A Calverley
COPD exacerbations {middle dot} 4: Prevention
Thorax,
May 1, 2006;
61(5):
440 - 447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, M. Wilks, G. C. Donaldson, and J. A. Wedzicha
Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD.
Chest,
February 1, 2006;
129(2):
317 - 324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G C Donaldson and J A Wedzicha
COPD exacerbations {middle dot} 1: Epidemiology
Thorax,
February 1, 2006;
61(2):
164 - 168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Vestbo and J C Hogg
Convergence of the epidemiology and pathology of COPD
Thorax,
January 1, 2006;
61(1):
86 - 88.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Mallia and S. L. Johnston
Mechanisms and Experimental Models of Chronic Obstructive Pulmonary Disease Exacerbations
Proceedings of the ATS,
November 1, 2005;
2(4):
361 - 366.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J J Soler-Cataluna, M A Martinez-Garcia, P Roman Sanchez, E Salcedo, M Navarro, and R Ochando
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Thorax,
November 1, 2005;
60(11):
925 - 931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
Thorax,
June 1, 2005;
60(6):
480 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E M Drost, K M Skwarski, J Sauleda, N Soler, J Roca, A Agusti, and W MacNee
Oxidative stress and airway inflammation in severe exacerbations of COPD
Thorax,
April 1, 2005;
60(4):
293 - 300.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lode, J. Eller, A. Linnhoff, M. Ioanas, and the Evaluation of Therapy-Free Interval in COPD Pa
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval
Eur. Respir. J.,
December 1, 2004;
24(6):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J R Hurst and J A Wedzicha
Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation
Postgrad. Med. J.,
September 1, 2004;
80(947):
497 - 505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.J. Sterk
Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1
Eur. Respir. J.,
April 1, 2004;
23(4):
497 - 498.
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the European Respiratory Society.
|